Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB03
- Development stage
- Preclinical
- Lead developer
- HealthBiome
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
HB03 is a live biotherapeutic product (LBT) consisting of the gut bacterium *Akkermansia muciniphila*, developed by the South Korean biotechnology company HealthBiome. Originating as a startup from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), HealthBiome is positioning HB03 to modulate the host microbiome and its associated immune and metabolic pathways. The drug is primarily being developed for oncology applications, where it is intended to be used either as a monotherapy or in combination with chemotherapy and immune checkpoint inhibitors. Preclinical studies have explored its efficacy across various malignancies, including colorectal, lung, pancreatic, melanoma, glioblastoma, and sarcoma. Beyond oncology, HB03 is also being investigated for its potential in treating metabolic and neurodegenerative diseases.
- Other names
- Akkermansia muciniphila
Beyond the preview
Go deeper on HB03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB03.